Anti-ATM Antibody, clone 4N19, ZooMAb^® Rabbit Monoclonal

rabbit (recombinant)

expressed in HEK 293 cells

unconjugated

purified antibody

primary antibodies

4N19, monoclonal
recombinant monoclonal

ZooMAb^® learn more

lyophilized

calculated mol wt 350.69 kDa
observed mol wt ~350 kDa

mouse, human, rat

pkg of 25 μL

Waste Prevention
Designing Safer Chemicals
Design for Energy Efficiency
Learn more about the Principles of Green Chemistry.

recombinant expression
Learn more about Antibody Enhanced Validation

affinity binding assay: suitable
immunofluorescence: suitable
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
western blot: suitable

IgG

Aligned

ambient

2-8℃

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.

Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.

Learn more about ZooMAb here.

Clone 4N19 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects ATM. It targets an epitope within 148 amino acids from the C-terminal region.

GST/His-tagged recombinant fragment corresponding to 148 amino acids from the C-terminal region of human ATM.

Anti-ATM, clone 4N19 ZooMAb, Cat. No. ZRB1376, a recombinant Rabbit monoclonal antibody that targets ATM and is tested in Affinity Binding Assay, Immunofluorescence, Immunohistochemistry (Paraffin), and Western Blotting.
Western Blotting Analysis: A 1:10,000 dilution from a representatve lot detected ATM in HeLa, NIH/3T3, and L6 cell lysate.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representatve lot detected ATM in human small intestine and human pancreas tissue sections.

Immunofluorescence Analysis: A 1:100 dilution from a representatve lot detected ATM in human kidney tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound human recombinant ATM with a KD of 3.6 x 10-6 in an affinity binding assay.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Serine-protein kinase ATM (UniProt: Q13315; also known as EC:2.7.11.1, Ataxia telangiectasia mutated, A-T mutated, ATM) is encoded by the ATM gene (Gene ID: 472) in human. ATM is a member of the phosphatidyl inositol 3-kinase-like kinase (PIKK) family that is activated in response to double-strand breaks (DSBs) induced by ionizing radiation and radiomimetic drugs. It is usually found localized near the damaged regions within several minutes indicting its damage-sensing role. After their recruitment to sites of DNA damage, ATM phosphorylate several intracellular substrates, including Chk1 and Chk2 that in turn target other proteins to induce cell-cycle arrest and allow DNA repair to proceed. In normal cells ATM is present as inert dimers or multimers, which dissociate into highly active ATM monomers following any DNA damage. During activation, ATM undergoes autophosphorylation on Ser1981 and the activated ATM undergoes additional phosphorylations and acetylation reactions. Defects in ATM signaling are commonly seen in human cancer cells and they affect the sensitivity of tumors to chemo- and radiation therapies. Mutations in ATM gene are known to cause Ataxia telangiectasia that is characterized by progressive cerebellar ataxia, dilation of the blood vessels in the conjunctiva and eyeballs, immunodeficiency, growth retardation and a strong predisposition to cancers. Defects in ATM may contribute to T-cell acute lymphoblastic leukemia and T-prolymphocytic leukemia. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Shiloh, Y., and Ziv, Y. (2013). Nat. Rev. Mol. Cell Biol. 14(4); 197-210).

Recommend storage of lyophilized product at 2-8℃; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8℃, or -20℃ for long term storage. Avoid repeated freeze-thaws.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

11 - Combustible Solids

WGK 1